Singapore authorities now reviewing telemed providers’ ads for weight-loss drugs
Lawyers say such advertisements may contravene a ban on ads for prescription medications
Add BT as a preferred source
SINGAPORE’S authorities are reviewing advertisements that telemedicine providers have put up for certain weight-loss drugs, while lawyers say that the providers could be in breach of a ban on advertisements of prescription-only medicines.
The telemedicine providers have put out ads for glucagon-like peptide 1 agonists, or GLP-1s, a class of drugs that are used to treat Type 2 diabetes but have gained attention for their effectiveness in aiding weight loss.
In response to queries, the Ministry of Health and the Health Sciences Authority said that they are reviewing the ads flagged by The Business Times and will take “appropriate enforcement action if any contraventions are detected”.
TRENDING NOW
Qatari LNG ship struck in Strait of Hormuz, testing US talks
DBS, OCBC and UOB shares hit all-time highs as sentiment improves
‘Baptism of fire’: Andre Khor on leading Singapore refiner Aster through an energy crisis
Singapore retains top spot as most expensive city for HNWIs, with five Apac cities in global top 10
